Efficacy and Safety on SOM3355 in Huntington's Disease Chorea

Brief summary (registry, in English)

Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington's Disease with choreic movements.

What you commit to

• Study type: Interventional · Phase 2
• Participants enrolled: 139
• From 2 Aug 2022 to the primary completion date, 25 Jun 2024
• 23 sites in 7 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Age in the registry: 21 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (23)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Related publications

• Safety and efficacy of SOM3355 in patients with Huntington's disease (SOMCT03): a phase 2b, randomised, placebo-controlled, multicentre, dose-ranging study.EClinicalMedicine · 2026 · PMID 42857615